Patrick Daly
Patrick Daly is an Assistant Editor at AMC Media Group.
Articles by Patrick Daly
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Jens Hillengass, MD, PhD, covers updates from CARTITUDE that show cilta-cel is effective in early lines of therapy in MM.
Researchers point to the poor outcomes observed with existing treatments. Here's what they found.
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Venetoclax plus azacitidine was well tolerated and achieved favorable response rates in higher-risk myelodysplastic syndrome.
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Researchers identified which co-occurring mutations had the strongest significance and what the high incidence could mean.
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.
Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.
A time-limited regimen including a PI3K inhibitor was safe and highly effective in patients with relapsed or refractory CLL.
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Interspersing cytarabine in R-CHOP induction therapy did not yield significant improvements in elderly patients with MCL.
BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.